In a significant development in diabetes and obesity care, Dr. Reddy’s Laboratories and Nestlé Health Science India have launched “Celevida GLP+”, a scientifically designed nutritional supplement aimed at supporting patients undergoing GLP-1 and GIP-based therapies for Type 2 diabetes and weight management.
The new formulation has been developed to address a growing concern among healthcare experts-muscle loss during rapid weight reduction therapies. Medical studies indicate that nearly 25% to 40% of weight lost during GLP-1 treatment may come from muscle mass, which can adversely affect metabolic health and long-term wellbeing.
Experts believe Indian patients are particularly vulnerable due to comparatively lower muscle mass, higher body fat percentage, and inadequate daily protein intake. While the average protein consumption in India is estimated at around 0.6 grams per kilogram of body weight, specialists recommend 1.2 to 1.5 grams during such therapies to preserve muscle strength and support recovery.
Celevida GLP+ has been formulated under the guidance of leading diabetologists and endocrinologists. The supplement contains Whey Protein Isolate for easy digestion and improved tolerance among patients experiencing gastrointestinal discomfort. Each 100 grams of the formulation provides 48 grams of protein along with Branched-Chain Amino Acids (BCAAs) and 27 essential nutrients, including Vitamins A and D, and Calcium.
M.V. Ramana, CEO – Branded Markets at Dr. Reddy’s Laboratories, said preserving muscle health alongside medication is crucial for sustainable diabetes and obesity management.
The product is now available across pharmacies, retail stores and major online platforms in India.
City Today News 9341997936
City Today News 
You must be logged in to post a comment.